Imidazolophthalazine derivatives as ligands for GABAA receptors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S248000, C544S115000, C544S234000

Reexamination Certificate

active

06946461

ABSTRACT:
A class of substituted imadazolo[2,1-a]phthalazine derivatives as ligands for GABAAreceptors of formula I:which are partial or full inverse agonists of an α5 receptor subunit while being relatively free of activity at α1 and/or α2 and/or α3 receptor subunit binding sites are described herein; they are therefore of benefit as a medicament for enhancing cognition but with the reduction or elimination of proconvulsant activity.

REFERENCES:
patent: 6013799 (2000-01-01), Shaw et al.
patent: 25 23 876 (1976-01-01), None
patent: WO 99 37644 (1999-07-01), None
patent: WO 00 12505 (2000-03-01), None
Maubach, Medline Abstract for Current Drug Targets-CNS & Neurological Disorders, vol. 2, p. 233-239 (2003).
Chemical Abstracts, vol. 119, No. 15, Oct. 11, 1993 Catarzi, D. et al, p. 22; col. 1; XP002179824 abstract & IL Farmaco, vol. 48, No. 4, 1993, pp. 447-457.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Imidazolophthalazine derivatives as ligands for GABAA receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazolophthalazine derivatives as ligands for GABAA receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolophthalazine derivatives as ligands for GABAA receptors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3432995

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.